Premedication for Pembrolizumab
Routine premedication with antipyretics and antihistamines is optional and may be considered, but is not required for pembrolizumab infusion. 1
Key Recommendation
According to the 2017 ESMO Clinical Practice Guidelines, pembrolizumab has a low infusion reaction (IR) rate of only 3%, presenting primarily as pyrexia and chills 1. Premedication with antipyretic (such as acetaminophen/paracetamol) and antihistamine (such as diphenhydramine) may be considered but is not mandatory 1.
This contrasts sharply with other immunotherapy agents:
- Daratumumab requires mandatory premedication (corticosteroid, antipyretic, antihistamine) due to 40-50% IR rates 1
- Rituximab requires premedication due to 77% first-infusion IR rates 1
- Panitumumab and trastuzumab explicitly do not recommend premedication 1
Clinical Context
The permissive "may be considered" language reflects pembrolizumab's favorable safety profile:
- Low overall IR incidence: Only 3% of patients experience infusion reactions 1
- Mild symptoms: When reactions occur, they typically manifest as low-grade fever and chills 1
- Severe reactions are rare: Grade 3-4 reactions requiring permanent discontinuation occur in <1% of patients 2
When Premedication Should Be Used
Premedication becomes advisable in specific circumstances:
After a prior infusion reaction: If a patient experienced an IR during a previous pembrolizumab infusion, premedication with antipyretics and antihistamines should be administered before subsequent doses 1
Successful rechallenge after severe reactions: A 2025 case report demonstrated successful pembrolizumab rechallenge after a grade 3 IR using premedication (histamine receptor inhibitors and acetaminophen) combined with dramatically reduced infusion rates (25-50% of normal) 3
Important Caveats
Do not confuse infusion reactions with immune-related adverse events (irAEs): Premedication addresses acute hypersensitivity during infusion, not the delayed immune-mediated toxicities (dermatologic, endocrine, gastrointestinal) that are the hallmark of checkpoint inhibitor therapy 4.
Corticosteroid premedication is NOT recommended for routine pembrolizumab administration, unlike some other immunotherapy agents. Corticosteroids are reserved for managing established immune-related adverse events, not prophylaxis 1.
Combination regimens may differ: When pembrolizumab is combined with other agents (e.g., enfortumab vedotin), the partner drug may require its own premedication protocol. For example, enfortumab vedotin combinations have used routine dexamethasone premedication in real-world practice 5.